MK-677 (Ibutamoren) and Metformin Interaction

Why This Interaction Matters

MK-677 and metformin pull glucose metabolism in opposite directions. That tension defines the clinical significance of combining these two agents. MK-677 stimulates growth hormone release by mimicking ghrelin at the GHS-R1a receptor. GH, in turn, promotes lipolysis and hepatic gluconeogenesis, both of which raise circulating glucose.

Metformin works the other side. It suppresses hepatic glucose output through AMPK activation and improves peripheral insulin sensitivity 1. The FDA label for metformin states that the drug "decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization" [2].

The practical concern is straightforward: MK-677 may partially or fully counteract the glucose-lowering effect a patient depends on. In Nass et al.'s two-year trial of MK-677 in healthy older adults (N=65), fasting glucose increased by an average of 0.3 mmol/L in the treatment group, with some participants developing impaired fasting glucose 3. For a patient on metformin for type 2 diabetes or prediabetes, that shift is not trivial. It can mean the difference between controlled and uncontrolled glycemia.

No pharmacokinetic drug-drug interaction has been identified. The two compounds do not share metabolic pathways, transporters, or binding proteins. The entire interaction is pharmacodynamic.

Pharmacokinetic Independence: Why There Is No CYP or Transporter Conflict

MK-677 is metabolized primarily by CYP3A4 in the liver 4. Metformin, by contrast, is not metabolized at all. It is excreted unchanged in the urine via organic cation transporters (OCT1 and OCT2) and the multidrug and toxin extrusion proteins MATE1 and MATE2-K 1.

This separation matters. Drugs that share CYP3A4 metabolism can compete for enzyme access, raising plasma levels of one or both agents. That does not happen here. MK-677 does not inhibit or induce OCT1/OCT2. Metformin does not affect CYP3A4 activity.

P-glycoprotein (P-gp) is another common site of drug interaction. While some GH secretagogues show P-gp affinity, published data on MK-677 do not indicate clinically meaningful P-gp inhibition at standard research doses of 25 mg daily. Metformin is not a P-gp substrate 5.

The bottom line: co-administration does not change the blood levels of either compound. You will absorb and clear the same amount of each drug whether taken alone or together. The interaction happens downstream, at the level of glucose regulation.

The Pharmacodynamic Conflict: GH-Driven Insulin Resistance vs. Insulin Sensitization

Growth hormone is diabetogenic. That statement comes directly from decades of endocrine research and is reflected in the Endocrine Society's 2011 Clinical Practice Guideline on GH deficiency, which notes that "GH replacement can impair glucose tolerance and that glucose homeostasis should be monitored" in patients receiving GH therapy 6.

MK-677 raises GH through a different mechanism than exogenous GH injection, but the metabolic downstream effects overlap significantly. In Copinschi et al.'s study of healthy young men given MK-677 for seven days, mean 24-hour GH concentrations increased by 97%, and fasting insulin rose by 50% without a corresponding drop in glucose, indicating reduced insulin sensitivity 7.

Svensson et al. reported similar findings in obese subjects treated with MK-677 for two months. Fasting glucose increased from 4.8 to 5.2 mmol/L (an 8.3% rise), and fasting insulin climbed by 26% 4. Fat-free mass increased by 3 kg, confirming the GH/IGF-1 axis was activated.

Metformin's mechanism directly opposes these effects. By activating AMPK in hepatocytes, metformin reduces the gluconeogenic drive that GH amplifies. By improving GLUT4-mediated glucose uptake in skeletal muscle, metformin partially compensates for the peripheral insulin resistance GH induces. The net glycemic effect of combining the two depends on dosing, duration, and individual metabolic reserve.

A patient with strong beta-cell function may tolerate the opposing signals without measurable glucose deterioration. A patient with diminished beta-cell reserve (common in type 2 diabetes and advancing prediabetes) may see fasting glucose escape upward despite stable metformin dosing.

Clinical Evidence From MK-677 Trials

MK-677 has been studied in several controlled trials, none of which specifically examined co-administration with metformin. The glucose and insulin data from these trials, however, provide the evidence base for predicting the interaction.

Nass et al. (2008), Annals of Internal Medicine. This randomized, double-blind trial enrolled 65 healthy adults aged 60 to 81 years. Participants received MK-677 25 mg or placebo daily for up to two years. IGF-1 levels increased to those of young adults. Fasting glucose rose significantly in the MK-677 group. Five MK-677 participants (compared to one on placebo) developed fasting glucose values meeting criteria for impaired fasting glucose or diabetes. The authors noted that "the increase in fasting blood glucose... raises concern about the long-term metabolic safety of ghrelin mimetics" 3.

Svensson et al. (1998), JCEM. In eight obese men treated with MK-677 25 mg daily for two months, fasting glucose rose 0.4 mmol/L and insulin rose 26%. Body weight increased by 3 kg, primarily as fat-free mass 4.

Murphy et al. (2001), JCEM. Postmenopausal women (N=292) received MK-677 25 mg daily, alendronate, or both for 12 months. The MK-677 groups showed increased IGF-1 and modest increases in fasting glucose. The glucose effect was consistent across subgroups 8.

Copinschi et al. (1996), JCEM. Seven-day treatment in healthy young men (N=32) produced a 97% increase in mean GH levels and a 50% rise in fasting insulin, indicating acute insulin resistance even in metabolically healthy subjects 7.

Across these trials, the pattern is consistent: MK-677 impairs glucose homeostasis in a dose-dependent, duration-dependent manner. The effect appears within the first week and persists with continued dosing.

Who Is at Highest Risk

Not every patient faces the same degree of risk from this interaction. Three populations deserve heightened caution.

Type 2 diabetes patients on metformin monotherapy. These patients already have impaired insulin secretion and hepatic insulin resistance. Adding a GH secretagogue can push fasting glucose above target ranges, potentially requiring metformin dose escalation or addition of a second glucose-lowering agent. The ADA Standards of Care recommend reassessing therapy if HbA1c rises above individualized targets [9].

Prediabetic individuals. Patients with fasting glucose between 5.6 and 6.9 mmol/L (100 to 125 mg/dL) who take metformin for diabetes prevention sit on a metabolic edge. MK-677's glucose-raising effect could accelerate conversion to overt diabetes. The Diabetes Prevention Program showed metformin reduced diabetes incidence by 31% over 2.8 years 10. That protective benefit could be partially eroded by concurrent MK-677 use.

Older adults. Age-related decline in beta-cell function makes older patients more sensitive to GH-mediated insulin resistance. The Nass et al. trial specifically enrolled older adults and documented the glucose impairment in this age group 3.

Younger, metabolically healthy individuals using MK-677 for body composition goals represent a lower-risk group. Their insulin reserve can typically compensate for the GH-driven glucose stress. Even so, monitoring remains appropriate.

Monitoring Protocol for Co-Administration

If a clinician determines that concurrent use is warranted, a structured monitoring approach reduces the risk of undetected glucose deterioration.

Baseline labs (before starting MK-677): fasting glucose, fasting insulin, HbA1c, lipid panel, and IGF-1. These values establish the metabolic starting point and provide comparison for follow-up.

Week 4 check: repeat fasting glucose and fasting insulin. A fasting glucose increase of more than 0.5 mmol/L (9 mg/dL) or fasting insulin increase exceeding 30% from baseline should trigger reassessment. Options include increasing metformin by 500 mg daily, reducing MK-677 dose, or discontinuing MK-677.

Week 8 and quarterly thereafter: fasting glucose, HbA1c, and fasting insulin. HbA1c reflects the prior two to three months of glycemic control and captures trends that spot checks miss.

Continuous glucose monitoring (CGM) offers the most granular view. Patients already wearing a CGM sensor (Libre, Dexcom) should review 14-day average glucose and time-in-range reports after initiating MK-677. A drop in time-in-range below 70% (for type 2 diabetes targets) or a rise in mean glucose above 154 mg/dL signals that the GH effect is outpacing metformin's benefit 9.

Dose Adjustment Considerations

Metformin dose increases are the first-line response if glucose rises during co-administration. The FDA-approved maximum for immediate-release metformin is 2 to 550 mg daily (850 mg three times daily) 2. Extended-release formulations allow up to 2 to 000 mg once daily.

If a patient is already at maximum metformin dosing and glucose control deteriorates with MK-677, the options narrow. Adding a second glucose-lowering agent (such as an SGLT2 inhibitor or GLP-1 receptor agonist) introduces additional complexity and cost. The simpler path is MK-677 dose reduction or discontinuation.

MK-677 dose-response data suggest that 10 mg daily produces a smaller GH/IGF-1 increase than 25 mg but still raises IGF-1 above baseline 8. A lower dose may preserve some of the desired anabolic effect while reducing glucose disruption. No head-to-head trial has tested this strategy with concurrent metformin.

Other Metabolic Effects to Watch

The interaction is not limited to glucose. GH increases lipolysis, which raises free fatty acids (FFAs) in circulation. Elevated FFAs can worsen hepatic insulin resistance independently of the direct GH effect on the liver 11. Metformin has modest FFA-lowering properties, but whether that effect is sufficient to offset GH-driven lipolysis in every patient is unknown.

Water retention is another concern. MK-677 causes dose-dependent fluid retention through GH-mediated sodium reabsorption. Patients may notice peripheral edema, particularly in the first four weeks. Metformin does not cause fluid retention and does not worsen this effect. However, if a patient also takes insulin or a sulfonylurea alongside metformin, the combined fluid retention and hypoglycemia risks multiply in unpredictable ways.

Cortisol is worth noting briefly. MK-677 can produce a transient 15 to 30% rise in morning cortisol levels 7. Cortisol is a counter-regulatory hormone that raises glucose. This adds a third mechanism, beyond direct GH action, by which MK-677 can oppose metformin's glucose-lowering effect.

Regulatory and Legal Context

MK-677 is not FDA-approved for any indication. It is classified as an investigational drug and is sold by research chemical suppliers, often without pharmaceutical-grade quality assurance. The FDA has issued warning letters to companies marketing GH secretagogues as dietary supplements.

Metformin, by contrast, has been FDA-approved since 1994 and is one of the most extensively studied medications in clinical use, with over 60 years of post-marketing data. This asymmetry in regulatory status and safety data matters. Clinicians advising patients about this combination must weigh a well-characterized medication against a compound with limited human trial data and no post-marketing surveillance.

Patients should inform their prescribing physician if they are using MK-677. The glucose effects documented in published trials are real, reproducible, and clinically relevant for anyone managing blood sugar with metformin.